TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares. The firm expects the company will achieve its goal of being the top-performing large-cap med tech company in 2024-26 if not longer. This can be accomplished with strong momentum in its commercial portfolio and contributions from new, differentiated products launched from its pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $107 from $98 at Citi
- Boston Scientific price target raised to $101 from $98 at Canaccord
- Boston Scientific participates in a conference call with Truist
- Boston Scientific to acquire Intera Oncology, terms not disclosed
- Boston Scientific Launches 2025 Incentive Programs